Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Travoprost Ophthalmic Solution Usp, 0.004%
Brand Name
Travoprost Ophthalmic Solution Usp, 0.004%
Generic Name
Travoprost Ophthalmic Solution Usp, 0.004%
Active Ingredient
TravoprostCategory
Prostaglandin Analog [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| .04 mg/mL | SOLUTION/ DROPS | OPHTHALMIC | 62332-510 |
Detailed information about Travoprost Ophthalmic Solution Usp, 0.004%
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Travoprost Ophthalmic Solution Usp, 0.004%, you must consult a qualified healthcare professional.
Travoprost is a highly potent prostaglandin F2α analog used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by increasing the outflow of aqueous humor through the uveoscleral pathway.
The standard adult dosage for Travoprost ophthalmic solution (0.004%) is one drop in the affected eye(s) once daily. Clinical studies have demonstrated that the medication is most effective when administered in the evening. Taking the medication at night aligns with the natural circadian rhythm of intraocular pressure and ensures that the drug's peak effect occurs during the morning hours when IOP often reaches its highest point.
It is critical to note that increasing the frequency of dosing (e.g., using it twice daily) may actually decrease the intraocular pressure-lowering effect. This phenomenon, sometimes called the 'prostaglandin paradox,' occurs because over-saturation of the receptors can lead to a compensatory response that reduces fluid outflow. Therefore, patients must strictly adhere to the once-daily regimen prescribed by their ophthalmologist.
The safety and effectiveness of Travoprost in pediatric patients (under the age of 16) have not been established through comprehensive clinical trials. While some pediatric ophthalmologists may use prostaglandin analogs off-label for childhood glaucoma, this is done with extreme caution. Parents should be aware that children may be more susceptible to systemic side effects or changes in iris pigmentation. Always consult a specialized pediatric ophthalmologist for guidance regarding children.
Because Travoprost is applied topically and has extremely low systemic absorption, no specific dosage adjustments are typically required for patients with kidney disease. However, patients with end-stage renal disease should be monitored for any unusual systemic reactions.
Similar to renal impairment, the systemic exposure to Travoprost is so minimal that hepatic (liver) impairment does not usually necessitate a change in the ophthalmic dose. The drug has been studied in patients with mild to severe hepatic impairment with no significant safety concerns reported.
No overall differences in safety or effectiveness have been observed between elderly and younger patients. The standard adult dose of one drop daily is appropriate for geriatric populations, provided they have the manual dexterity to administer the drops correctly.
Proper administration technique is vital to ensure the medication reaches the eye and to minimize systemic absorption:
If you miss a dose of Travoprost, skip the missed dose and wait until your next scheduled dose the following evening. Do not apply extra drops to make up for a missed dose. Maintaining a consistent schedule is the best way to keep your eye pressure stable.
A systemic overdose from topical application is highly unlikely. However, if multiple drops are accidentally instilled, the eye may become very red, watery, and irritated. If the contents of the bottle are accidentally swallowed, contact a poison control center or seek emergency medical care. Symptoms of systemic ingestion might include fainting, dizziness, or shortness of breath, though these are rare given the low concentration of the drug.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as this can lead to a dangerous spike in eye pressure.
The most frequently reported side effect of Travoprost is ocular hyperemia, which occurs in 30% to 50% of patients. This is a redness of the white part of the eye caused by the dilation of small blood vessels. While it may look alarming, it is usually painless and often diminishes over the first few weeks of treatment as the eye adjusts to the medication.
Another very common effect is eyelash changes. Patients often notice that their lashes become longer, thicker, darker, and more numerous. While some consider this a cosmetic benefit, it can be asymmetrical if only one eye is being treated. These changes are typically reversible if the medication is discontinued.
While Travoprost is generally well-tolerated, some reactions require urgent medical evaluation.
> Warning: Stop taking Travoprost and call your doctor immediately if you experience any of the following:
The most notable long-term effect is the permanent change in iris color. This change develops slowly and may not be noticed for several months or even years. It is most common in patients with mixed-colored eyes (e.g., blue-brown, grey-brown, or yellow-brown). If you have purely blue or green eyes, the risk is lower but still present.
Additionally, skin darkening (hyperpigmentation) of the eyelids may occur. Unlike the iris color change, eyelid darkening is often reversible if the medication is stopped. Long-term use may also lead to a permanent increase in the length and thickness of the eyelashes.
There are currently no FDA black box warnings for Travoprost. It is considered a safe medication when used as directed under the supervision of an eye care professional.
Report any unusual symptoms, especially changes in your vision or the appearance of your eyes, to your healthcare provider during your regular check-ups.
Travoprost is intended for ophthalmic (eye) use only. It should never be injected or swallowed. Patients must be aware that the results of treatment—specifically the lowering of eye pressure—are only maintained as long as the medication is used. If the drops are discontinued, the intraocular pressure will likely return to its pre-treatment levels within several weeks, increasing the risk of vision loss from glaucoma.
No FDA black box warnings for Travoprost. However, the FDA-approved labeling contains specific 'Precautions' regarding iris pigmentation and eyelash changes that patients must be informed of before starting therapy.
Patients using Travoprost require regular follow-up appointments with an ophthalmologist or optometrist. Monitoring typically includes:
Travoprost may cause temporary blurred vision immediately after the drops are instilled. Patients should wait until their vision clears before driving a vehicle or operating heavy machinery. For most patients, this takes only a few minutes.
There are no known direct interactions between Travoprost and alcohol. However, excessive alcohol consumption can sometimes affect intraocular pressure and overall eye health. It is best to discuss your alcohol intake with your doctor.
Do not stop using Travoprost abruptly without consulting your doctor. Glaucoma is a 'silent' disease, meaning you will not feel your eye pressure rising. Stopping the medication could lead to a rapid increase in pressure that damages the optic nerve without you realizing it. There is no 'withdrawal syndrome' associated with Travoprost, but the loss of therapeutic effect is immediate.
> Important: Discuss all your medical conditions, especially any history of eye inflammation or surgeries, with your healthcare provider before starting Travoprost.
There are no drugs that are strictly contraindicated for use with Travoprost. However, the use of two or more different prostaglandin analogs (e.g., using Travoprost and Latanoprost simultaneously) is strongly discouraged. Using multiple drugs from this same class can actually lead to an increase in intraocular pressure rather than a further decrease. This is due to the saturation of the FP receptors and a potential inflammatory response in the eye's drainage tissues.
Because Travoprost is administered topically to the eye and has negligible systemic absorption, there are no known interactions with specific foods, including grapefruit, dairy, or high-fat meals. Your diet does not need to change while using this medication.
Travoprost does not typically interfere with standard blood or urine laboratory tests. Because the systemic concentration is so low (often below the level of detection), it does not affect liver enzymes, kidney function markers, or blood cell counts.
To safely manage potential interactions:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, even if they are not for your eyes.
Travoprost must NEVER be used in the following circumstances:
In these situations, a healthcare provider will perform a careful risk-benefit analysis before prescribing Travoprost:
Patients who have had a severe allergic reaction to other prostaglandin analogs, such as Latanoprost (Xalatan), Bimatoprost (Lumigan), or Tafluprost (Zioptan), may also react to Travoprost. The chemical structures are similar enough that cross-sensitivity is a legitimate clinical concern. If you have reacted to another glaucoma drop in the past, ensure your ophthalmologist is aware of the specific brand and the nature of your reaction.
> Important: Your healthcare provider will evaluate your complete medical history, including any past eye surgeries or inflammatory conditions, before prescribing Travoprost.
Travoprost is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (such as increased pregnancy loss or skeletal abnormalities at very high systemic doses), but there are no adequate and well-controlled studies in humans.
Because systemic exposure from eye drops is very low, the risk to a human fetus is likely small. However, the drug should be used during pregnancy only if the potential benefit to the mother outweighs the potential risk to the unborn child. Pregnant women should use nasolacrimal occlusion (pressing the corner of the eye) to further reduce any systemic absorption. If you are planning a pregnancy, discuss alternative treatments with your ophthalmologist.
It is not known whether Travoprost or its metabolites are excreted in human milk. In animal studies (rats), Travoprost and its metabolites were shown to pass into milk. Because many drugs are excreted in human milk, caution should be exercised when Travoprost is administered to a nursing woman. The decision to continue breastfeeding or the drug should take into account the importance of the drug to the mother's eye health.
Travoprost is not FDA-approved for use in children under the age of 16. The primary concern in pediatric populations is the potential for increased iris pigmentation, which could be more distressing in a child with a long life expectancy. Furthermore, the long-term effects of prostaglandin analogs on the developing eye are not fully understood. If a doctor prescribes this off-label for a child, they will monitor the child's eye pressure and eye appearance very closely.
No overall differences in safety or effectiveness have been observed between elderly (65 years and older) and younger adult patients. Glaucoma is much more common in the elderly, making this a primary target population for Travoprost. One practical concern for geriatric patients is the ability to physically administer the drops. Conditions like arthritis or tremors may make it difficult to squeeze the bottle or aim the drop correctly. In such cases, the use of an 'eye drop aid' or assistance from a caregiver is recommended.
Travoprost has been studied in patients with renal impairment (from mild to severe). Because the drug is rapidly inactivated in the bloodstream and the total daily dose is extremely small (about 1.2 micrograms per drop), no dosage adjustments are necessary for patients with kidney disease. It is not expected to be removed by dialysis in any significant amount.
Clinical trials have included patients with hepatic impairment (Child-Pugh Class A, B, and C). No clinically significant changes in heart rate, blood pressure, or systemic safety were noted in these patients. Therefore, no dosage adjustment is required for patients with liver disease.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, nursing, or have significant organ impairment.
Travoprost is a synthetic analog of prostaglandin F2α. Its primary mechanism of action is as a selective FP prostanoid receptor agonist. These receptors are found in high concentrations within the ciliary muscle and the trabecular meshwork of the eye.
When Travoprost binds to these receptors, it initiates a complex signaling pathway that results in the remodeling of the extracellular matrix within the ciliary muscle. This increases the space between muscle bundles, thereby significantly increasing the uveoscleral outflow of aqueous humor. While most of the eye's fluid normally drains through the trabecular meshwork, the uveoscleral pathway serves as a secondary 'overflow' route. By opening this route, Travoprost effectively lowers the intraocular pressure (IOP).
| Parameter | Value |
|---|---|
| Bioavailability | High ocular penetration; <1% systemic |
| Protein Binding | ~80% (systemic free acid) |
| Half-life | <45 minutes (systemic free acid) |
| Tmax (Aqueous Humor) | 1 - 2 hours |
| Metabolism | Hydrolysis by esterases (cornea); Beta-oxidation |
| Excretion | Rapidly cleared; <2% in urine |
Travoprost is categorized as a Prostaglandin Analog. It is part of a therapeutic class that includes other well-known medications such as Latanoprost, Bimatoprost, and Tafluprost. These drugs have largely replaced beta-blockers as the first-line therapy for glaucoma due to their superior efficacy and favorable systemic safety profile.
Common questions about Travoprost Ophthalmic Solution Usp, 0.004%
Travoprost is an ophthalmic solution primarily used to lower high pressure inside the eye in patients with open-angle glaucoma or ocular hypertension. By reducing this pressure, the medication helps prevent damage to the optic nerve, which is essential for maintaining clear vision. It belongs to a class of drugs called prostaglandin analogs, which work by improving the natural drainage of fluid from the eye. It is typically prescribed as a long-term, daily treatment to manage these chronic conditions. Your healthcare provider will determine if it is the most appropriate choice based on your eye health history.
The most common side effect is eye redness, also known as conjunctival hyperemia, which affects up to half of all users. Many patients also notice that their eyelashes become longer, thicker, and darker over time. A significant and potentially permanent side effect is a change in eye color, where the iris becomes more brown due to increased pigment. Other common issues include mild eye irritation, stinging, or a feeling that something is in the eye. Most of these effects are localized to the eye and do not affect the rest of the body.
There is no known direct interaction between Travoprost eye drops and alcohol consumption. Because the medication is applied topically to the eye and very little enters the bloodstream, moderate alcohol use is generally considered safe. However, it is important to remember that alcohol can occasionally influence eye pressure and overall hydration, which are relevant to glaucoma management. Always follow the general health advice provided by your doctor regarding alcohol. If you experience dizziness or blurred vision, you should exercise extra caution.
Travoprost is classified as Pregnancy Category C, meaning its safety in human pregnancy has not been fully established. Animal studies have shown some risks to the fetus at very high doses, but human data is lacking. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits with your ophthalmologist. In some cases, your doctor may suggest alternative treatments or specific techniques, like nasolacrimal occlusion, to minimize the amount of drug that reaches the baby. Never start or stop this medication during pregnancy without professional medical guidance.
Travoprost begins to lower intraocular pressure within about 2 hours after the first drop is administered. The maximum effect, or peak reduction in pressure, usually occurs about 12 hours after application. Because it has a long duration of action, the pressure-lowering effect lasts for at least 24 hours, which is why it is only used once a day. It may take several weeks of consistent use for your doctor to determine the full extent of the drug's effectiveness for your eyes. Regular follow-up appointments are necessary to monitor these results.
You should not stop taking Travoprost suddenly unless specifically instructed by your healthcare provider. Glaucoma and ocular hypertension are chronic conditions that require consistent management to prevent vision loss. If you stop the medication, your eye pressure will likely return to its previous high levels within a few weeks, putting your optic nerve at risk. Since high eye pressure usually has no symptoms, you won't feel the damage occurring. If you are experiencing side effects that make you want to stop, contact your doctor to discuss alternative medications.
If you miss a dose of Travoprost, you should skip the missed dose and simply apply the next dose at your regularly scheduled time the following evening. Do not apply two drops or 'double up' to make up for the missed dose, as this can actually make the medication less effective and increase the risk of side effects. Consistency is key for controlling glaucoma, so try to incorporate the drops into your nightly routine. If you find yourself frequently forgetting doses, talk to your doctor about strategies or tools to help you remember.
There is no clinical evidence to suggest that Travoprost causes weight gain. Because the medication is applied topically to the eye and is rapidly cleared from the systemic circulation, it does not have the systemic metabolic effects associated with drugs like oral steroids. If you experience unexpected weight changes while using Travoprost, it is likely due to other factors such as diet, lifestyle, or other medications you may be taking. You should discuss any significant changes in your weight or overall health with your primary care physician to identify the underlying cause.
Travoprost can generally be taken with other medications, but you must inform your doctor about all the drugs you use, including other eye drops. If you use multiple types of eye drops, you should wait at least 5 minutes between each one to ensure they are properly absorbed. Using Travoprost with other prostaglandin analogs (like Latanoprost) is not recommended, as it can actually interfere with pressure control. Systemic medications usually do not interact with Travoprost, but your ophthalmologist needs a full medical history to ensure the safest possible treatment plan.
Yes, Travoprost is available as a generic medication, which is typically more cost-effective than the brand-name versions like Travatan Z. Generic versions are required by the FDA to have the same active ingredient, strength, and efficacy as the brand-name drug. However, the inactive ingredients, such as the preservatives used to keep the solution sterile, may differ between the generic and brand-name products. Some patients with very sensitive eyes may prefer specific formulations. Your pharmacist or doctor can help you decide which version is best for your needs and insurance coverage.
Other drugs with the same active ingredient (Travoprost)